NASDAQ:MGTA - Magenta Therapeutics Stock Price Target and Predictions

  • Consensus Rating: Buy
  • Consensus Price Target: $19.00
  • Forecasted Upside: 169.50 %
  • Number of Analysts: 5
  • Breakdown:
  • 0 Sell Ratings
  • 0 Hold Ratings
  • 5 Buy Ratings
  • 0 Strong Buy Ratings
$7.05
▼ -0.02 (-0.28%)
1 month | 3 months | 12 months
Get New Magenta Therapeutics Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for MGTA and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for MGTA

i We calculate consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). Our consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. Our consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
$19.00
▲ +169.50% Upside Potential
This price target is based on 5 analysts offering 12 month price targets for Magenta Therapeutics in the last 3 months. The average price target is $19.00, with a high forecast of $22.00 and a low forecast of $15.00. The average price target represents a 169.50% upside from the last price of $7.05.
Buy
The current consensus among 5 polled investment analysts is to buy stock in Magenta Therapeutics.

Past Monthly Recommendations

Move your mouse over past months for details

  • 0 strong buy ratings
  • 5 buy ratings
  • 0 hold ratings
  • 0 sell ratings
5/2/2019
  • 0 strong buy ratings
  • 3 buy ratings
  • 0 hold ratings
  • 0 sell ratings
7/31/2019
  • 0 strong buy ratings
  • 4 buy ratings
  • 0 hold ratings
  • 0 sell ratings
10/29/2019
  • 0 strong buy ratings
  • 5 buy ratings
  • 0 hold ratings
  • 0 sell ratings
1/27/2020
  • 0 strong buy ratings
  • 4 buy ratings
  • 0 hold ratings
  • 0 sell ratings
4/26/2020
  • 0 strong buy ratings
  • 4 buy ratings
  • 0 hold ratings
  • 0 sell ratings
7/25/2020
  • 0 strong buy ratings
  • 4 buy ratings
  • 0 hold ratings
  • 0 sell ratings
9/23/2020
  • 0 strong buy ratings
  • 5 buy ratings
  • 0 hold ratings
  • 0 sell ratings
10/23/2020

Latest Recommendations

  • 0 strong buy ratings
  • 5 buy ratings
  • 0 hold ratings
  • 0 sell ratings

DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
10/14/2020JPMorgan Chase & Co.Initiated CoverageOverweightHigh
i
8/13/2020WedbushReiterated RatingOutperform$22.00Low
i
Rating by David Nierengarten at Wedbush
6/12/2020WedbushReiterated RatingBuy$22.00Medium
i
Rating by David Nierengarten at Wedbush
6/8/2020Goldman Sachs GroupUpgradeNeutral ➝ Buy$15.00High
i
1/13/2020CowenReiterated RatingBuyLow
i
Rating by Marc Frahm at Cowen Inc
12/9/2019CowenReiterated RatingBuyHigh
i
Rating by Marc Frahm at Cowen Inc
12/6/2019BTIG ResearchInitiated CoverageBuy$20.00Medium
i
12/6/2019Goldman Sachs GroupReiterated RatingNeutral$18.00High
i
11/13/2019CowenReiterated RatingBuyHigh
i
Rating by Marc Frahm at Cowen Inc
11/6/2019CowenReiterated RatingBuyMedium
i
8/8/2019CowenReiterated RatingBuyMedium
i
5/10/2019WedbushReiterated RatingOutperform$22.00High
i
3/24/2019Goldman Sachs GroupDowngradeBuy ➝ Neutral$17.00 ➝ $16.00High
i
3/14/2019Raymond JamesInitiated CoverageOutperform ➝ OutperformHigh
i
7/16/2018CowenInitiated CoverageOutperformHigh
i
7/16/2018JPMorgan Chase & Co.Initiated CoverageOverweight$18.00High
i
7/16/2018Goldman Sachs GroupInitiated CoverageBuy$18.00High
i
7/16/2018WedbushInitiated CoverageOutperform$22.00High
i
Rating by D. Nierengarten at Wedbush
(Data available from 10/23/2015 forward)
Magenta Therapeutics logo
Magenta Therapeutics, Inc., a clinical-stage biotechnology company, develops novel medicines to extend the curative power of stem cell transplant, gene therapy, genome editing, and cell therapy to patients. It is developing C100, C200, and C300 targeted antibody-drug conjugates for transplant conditioning; MGTA-145, a novel stem cell mobilization product candidate to control stem cell mobilization; MGTA-456, an allogeneic stem cell therapy to control stem cell growth; E478, a small molecule aryl hydrocarbon receptor antagonist for the expansion of gene-modified stem cells; and G100, an antibody-drug conjugate program to prevent acute graft and host diseases. The company was formerly known as HSCTCo Therapeutics, Inc. and changed its name to Magenta Therapeutics, Inc. in February 2016. Magenta Therapeutics, Inc. was founded in 2015 and is headquartered in Cambridge, Massachusetts.
Read More

Today's Range

Now: $7.05
$6.77
$7.15

50 Day Range

MA: $7.19
$6.52
$8.16

52 Week Range

Now: $7.05
$5.76
$16.19

Volume

629,963 shs

Average Volume

223,275 shs

Market Capitalization

$340.18 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

2.58